Medtech

Abbott ABT

ABBOTT LABORATORIESPharmaceutical PreparationsIL

Pipeline — registered trials by phase

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

— · Arthritis, Psoriatic · Completed · est. 2004-03

Remission in Subjects With Crohn's Disease, 1 Year Phase

— · Crohn's Disease · Completed · est. 2005-01

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

— · Human Immunodeficiency Virus Infections · Completed · est. 2008-07

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

— · Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia · Completed · est. 2007-02

Efficacy and Safety of Adalimumab in Patients With Active Uveitis

— · Uveitis · Completed · est. 2014-07

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

— · Functional Dyspepsia · Completed · est. 2025-02-28

Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

— · Crohn's Disease · Completed · est. 2008-07

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

— · Psoriatic Arthritis · Completed

Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease

— · Crohn's Disease · Completed · est. 2016-11-03

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season

— · Influenza · Completed · est. 2010-07

Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension

— · Essential Hypertension · Completed · est. 2013-04

Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption

— · Intrahepatic Cholestasis Associated With Alcoholic Liver Disease · Completed · est. 2015-02

The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents

— · Migraine · Completed

Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa

— · Hidradenitis Suppurativa (HS) · Completed · est. 2014-04

Study of Adalimumab in Patients With Axial Spondyloarthritis

— · Axial Spondyloarthritis · Completed · est. 2011-02

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

— · Moderate to Severe Plaque Psoriasis · Completed · est. 2009-04

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

— · Crohn's Disease · Completed

Evaluation of a Novel Human Milk Fortifier in Preterm Infants

— · Preterm Infants · Completed · est. 2012-12

Source: ClinicalTrials.gov (trials where Abbott is lead sponsor; 76 active or completed) and Drugs@FDA (1 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.

SEC filings — insider trading forms excluded

8-K2026-08-20Current report (material event)
10-Q2026-07-28Quarterly report
8-K2026-07-16Current report (material event)
11-K2026-06-1811-K
SD2026-05-27SD
SCHEDULE 13G2026-04-29SCHEDULE 13G
10-Q2026-04-29Quarterly report
8-K2026-04-27Current report (material event)
S-82026-04-24Employee stock plan
8-K2026-04-17Current report (material event)
8-K2026-04-16Current report (material event)
SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
S-82026-03-23Employee stock plan
8-K2026-03-23Current report (material event)
ARS2026-03-13Annual report to holders
DEFA14A2026-03-13DEFA14A
DEF 14A2026-03-13Proxy statement
8-K2026-03-09Current report (material event)
8-K2026-02-26Current report (material event)
424B52026-02-25Prospectus (offering)
FWP2026-02-24FWP
424B32026-02-23424B3
S-3ASR2026-02-23S-3ASR
8-K2026-02-20Current report (material event)
10-K2026-02-20Annual report
8-K2026-01-22Current report (material event)
8-K2025-12-12Current report (material event)
SCHEDULE 13G/A2025-12-03SCHEDULE 13G/A
8-K2025-11-21Current report (material event)
8-K2025-11-20Current report (material event)
10-Q2025-10-29Quarterly report
8-K2025-10-15Current report (material event)
10-Q2025-07-30Quarterly report
8-K2025-07-17Current report (material event)
11-K2025-06-2011-K
SD2025-05-29SD
8-K2025-05-01Current report (material event)
10-Q2025-04-30Quarterly report
8-K2025-04-28Current report (material event)
8-K2025-04-16Current report (material event)

Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.